Clinical Trial Update: Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating simplified 8-week monitoring for Glecaprevir/Pibrentasvir in chronic hepatitis C patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (glecaprevir/pibrentasvir)

Snippet

Sponsor: Kirby Institute | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2019-12-11